Home / News / News Releases / BCA Releases Statement on Pseudoephedrine Bill (HB 88)

BCA Releases Statement on Pseudoephedrine Bill (HB 88)

BCA President and CEO William J. Canary released the following statement today regarding HB 88, more commonly referred to as the Pseudoephedrine Bill.

“The proposed legislation (HB 88) would require individuals to obtain a prescription for products containing common cold and allergy remedies such as pseudoephedrine, ephedrine, and phenylpropamine, in an effort to combat the manufacturing of methamphetamine. While the BCA recognizes the critical need to eliminate meth labs in Alabama, requiring all employees to take time off work to visit their physician to obtain a prescription for common cold and allergy medications would result in increased employee health care costs and reduced worker productivity.  We look forward to supporting legislation being proposed and introduced by Sen. Holtzclaw and Rep. Galliher that will contain health care costs while ensuring we all engage in the fight against meth production in Alabama.”

More info: Contact Nathan Lindsay, 334-834-6000


About Nancy Hewston

Nancy Hewston
Vice President of Communications, Strategic Information and Federal Affairs
334-240-8725 | Fax: 334-241-5984
Email Nancy Wall Hewston

Check Also

BCA’s Canary Announces Departure, Accepts Position at U.S. Chamber

    FOR IMMEDIATE RELEASE: JULY 6, 2018 MONTGOMERY, Ala. – Business Council of Alabama …